Document

SD 1 formsdmay282026.htm SD Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM SD

SPECIALIZED DISCLOSURE REPORT

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts

001-14041

04-2882273

(State or other jurisdiction

of incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification No.)


125 Summer Street, Boston, MA						02110
(Address of principal executive offices)						(Zip Code)


James C. D’Arecca Executive Vice President, Chief Financial Officer (781) 848-7100
(Name and telephone number, including area code, of the person to contact in connection with this report)


Check the appropriate box to indicate the rule pursuant to which this Form is being submitted, and provide the period to which the information in this Form applies:

☒			Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025.

☐			Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended _____.

Section 1 - Conflict Minerals Disclosure

Item 1.01 Conflict Minerals Disclosure and Report

Pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, Haemonetics Corporation (the “Company”) has filed this Form SD for the reporting period from January 1, 2025 to December 31, 2025.

A copy of the Company’s Conflict Minerals Report is provided as Exhibit 1.01 to this Form SD and is publicly available at http://www.haemonetics.com/about-us/corporate-responsibility/conflict-minerals-statement. The information contained on our website is not incorporated by reference into this Form SD or our Conflict Minerals Report and should not be considered part of this Form SD or the Conflict Minerals Report.

Item 1.02 Exhibit

Item 3.01 of this Form SD is incorporated by reference into this Item 1.02.

Section 2 - Resource Extraction Issuer Disclosure

Item 2.01 Resource Extraction Issuer Disclosure and Report

Not applicable.

Section 3 - Exhibits

Item 3.01 Exhibits


Exhibit Number						Description
1.01						Conflict Minerals Report of Haemonetics Corporation for the calendar year ended December 31, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

HAEMONETICS CORPORATION

By:

/s/ James C. D’Arecca

Date: May 27, 2026

Name:

James C. D’Arecca

Title:

Executive Vice President, Chief Financial Officer

SEC Form SD filed by Haemonetics Corporation